DE69229857T2 - Zusammensetzung zur verwendung in der transdermalen verabreichung - Google Patents

Zusammensetzung zur verwendung in der transdermalen verabreichung

Info

Publication number
DE69229857T2
DE69229857T2 DE69229857T DE69229857T DE69229857T2 DE 69229857 T2 DE69229857 T2 DE 69229857T2 DE 69229857 T DE69229857 T DE 69229857T DE 69229857 T DE69229857 T DE 69229857T DE 69229857 T2 DE69229857 T2 DE 69229857T2
Authority
DE
Germany
Prior art keywords
composition
biologically active
active agent
transdermal administration
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69229857T
Other languages
English (en)
Other versions
DE69229857D1 (de
Inventor
Reginald Taylor
David Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transdermal Technologies Pty Ltd Laurieton New
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/795,499 external-priority patent/US5308621A/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of DE69229857D1 publication Critical patent/DE69229857D1/de
Application granted granted Critical
Publication of DE69229857T2 publication Critical patent/DE69229857T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69229857T 1991-02-18 1992-02-18 Zusammensetzung zur verwendung in der transdermalen verabreichung Expired - Fee Related DE69229857T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPK465191 1991-02-18
AUPK784791 1991-08-19
AUPK784691 1991-08-19
AUPK784891 1991-08-19
US07/795,499 US5308621A (en) 1991-02-18 1991-11-21 Ascorbic acid composition and transdermal administration method
PCT/AU1992/000058 WO1992014442A1 (en) 1991-02-18 1992-02-18 Composition for use in transdermal administration

Publications (2)

Publication Number Publication Date
DE69229857D1 DE69229857D1 (de) 1999-09-30
DE69229857T2 true DE69229857T2 (de) 2000-04-20

Family

ID=27507420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229857T Expired - Fee Related DE69229857T2 (de) 1991-02-18 1992-02-18 Zusammensetzung zur verwendung in der transdermalen verabreichung

Country Status (7)

Country Link
EP (1) EP0572494B1 (de)
JP (1) JPH06508100A (de)
AT (1) ATE183639T1 (de)
AU (1) AU668679B2 (de)
CA (1) CA2103725C (de)
DE (1) DE69229857T2 (de)
WO (1) WO1992014442A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3123193A (en) * 1991-12-13 1993-07-19 G.D. Searle & Co. Transdermal azidothymidine
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
DE4332093C2 (de) * 1993-09-22 1995-07-13 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Acetylsalicylsäure und Verfahren zu seiner Herstellung
US6103267A (en) * 1998-07-27 2000-08-15 Sunsmart, Inc. Stabilized ascorbic acid, composition, and method of use
JP2003040763A (ja) * 2001-05-23 2003-02-13 Taisho Pharmaceut Co Ltd 多価アルコール含有軟膏剤基剤
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR751951A (fr) * 1933-03-02 1933-09-13 Procédé d'hydrophilisation des corps gras
FR948326A (fr) * 1947-06-24 1949-07-28 Brillantine à base d'hormones
US4156736A (en) * 1976-05-28 1979-05-29 Sanol Schwarz-Monheim Gmbh Supersaturated isosorbide dinitrate solution, process for its production and its use
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
GB8629639D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
ATE42901T1 (de) * 1984-03-05 1989-05-15 Nitto Denko Corp Haftendes arzneimittelpraeparat fuer perkutane absorption.
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
JPH066534B2 (ja) * 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
GB8629640D0 (en) * 1986-12-11 1987-01-21 Beecham Group Plc Composition & method
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen

Also Published As

Publication number Publication date
CA2103725C (en) 2002-06-04
JPH06508100A (ja) 1994-09-14
DE69229857D1 (de) 1999-09-30
AU668679B2 (en) 1996-05-16
WO1992014442A1 (en) 1992-09-03
AU1272392A (en) 1992-09-15
EP0572494A1 (de) 1993-12-08
EP0572494B1 (de) 1999-08-25
ATE183639T1 (de) 1999-09-15
EP0572494A4 (en) 1996-05-29
CA2103725A1 (en) 1992-08-19

Similar Documents

Publication Publication Date Title
DE69229857D1 (de) Zusammensetzung zur verwendung in der transdermalen verabreichung
ATE56869T1 (de) Lang wirksame cefaclor-formulierung und deren herstellung.
YU98792A (sh) Postupci za dobijanje visokodoznih preparata kolagenaze
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
DE68921814D1 (de) VIP-Konjugate und deren aktive Fragmente mit hydrophoben Anteilen und topische Zuberetungen zur Verwendung in der Behandlung männlicher Impotenz.
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
ATA186692A (de) Pharmazeutische zusammensetzung
HK1003137A1 (en) New pyrazine derivatives their preparation and their use
PH23003A (en) Piroxicam monohydrate and aqueous pharmaceutical formulations containing same
HUT57203A (en) Process for substituted benzimidazol and paharmaceutical composition containing them
UA37206C2 (uk) Фармацевтична композиція, яка містить алкілсульфонамід-агоніст 5нті- подібного рецептора для ректального введення
SE8600496D0 (sv) Pharmaceutical 9,10-dihydro ergot alkaloid containing compositions
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
DE3783923T3 (de) Einen Wirkstoff und ein in Wasser quellendes Polymer enthaltendes Arzneimittel.
ATE238063T1 (de) Wässrige zusammensetzung mit verzögerter freisetzung, enthaltend rinderwachstumshormon- freisetzungsfaktor
Iwata et al. Interaction between thymopoietin and facteur thymique serique in the rosette inhibition assay
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
DK0741579T3 (da) Vandig formulering med forhalet frigivelse
KR900017599A (ko) 종양 치료용 약학 조성물
FR2585020B1 (fr) Nouvelle substance biologiquement active, appelee girolline, extraite de l'eponge pseudaxinyssa cantharella, son procede de preparation et les compositions pharmaceutiques qui la contiennent
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
ATE97806T1 (de) Fluessige nitrofurantoinsuspension.
SE8604780D0 (sv) Nikotinkompositioner for att minska obehagseffekter vid nikotinadministration och for att oka hallbarheten pa nikotinberedningar
BG90361A (en) Composition and method for the preparation of water soluble powder containing erythromycin thiocyanate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TRANSDERMAL TECHNOLOGIES PTY LTD., LAURIETON, NEW

8339 Ceased/non-payment of the annual fee